ARNA - ARNA STOCK NEWS

Arena Pharmaceuticals (Nasdaq: ARNA) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:00 AM ET. The presentation will be led by Amit D. Munshi, the Company's President and CEO. A live webcast will be available on Arena's investor relations page, with a recording accessible for 30 days post-event. Arena is committed to delivering vital medicines and adapting to global market changes.

Arena Pharmaceuticals (Nasdaq: ARNA) announced on December 15, 2020, that its Compensation Committee granted inducement stock options and restricted stock units (RSUs) to five new employees. The total grant includes 141,975 stock options and 2,460 RSUs, both having a grant date of December 15, 2020. The stock options have a seven-year term with an exercise price of $71.26, while both options and RSUs vest over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) to attract new talent.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced the presentation of topline results from the Phase 2b ADVISE trial for etrasimod, a novel oral treatment for moderate-to-severe atopic dermatitis, at the Revolutionizing Atopic Dermatitis (RAD) 2020 Virtual Conference. The findings support etrasimod's potential as an effective once-daily therapy. Etrasimod is designed for various immune-mediated diseases but remains investigational and unapproved.

Arena Pharmaceuticals (Nasdaq: ARNA) announced achieving its enrollment target of 372 participants for the Phase 3 ELEVATE UC 52 trial, assessing etrasimod for moderately-to-severely active ulcerative colitis. Although the trial reached its goal, screening will be extended by three weeks to accommodate additional participants. Topline data for both ELEVATE UC 52 and UC 12 trials is anticipated in Q1 2022. Etrasimod, an investigational oral drug, targets immune-mediated inflammatory diseases and is undergoing evaluation in over 400 global sites.

Arena Pharmaceuticals (Nasdaq: ARNA) announced a leadership transition in its R&D department, appointing Paul D. Streck, M.D., as Senior Vice President, Clinical Development, and Chief Medical Officer, effective December 1, 2020. This change follows the retirement of Chris Cabell, M.D., who served as the Executive Vice President and Chief Medical Officer since June 2020. Dr. Streck brings over 25 years of experience in drug development and has held leadership roles that led to several successful product launches.

Arena Pharmaceuticals (Nasdaq: ARNA) announced that CEO Amit D. Munshi will participate in a virtual fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on December 1, 2020, at 4:20 PM ET. A live webcast will be accessible on Arena's investor relations page at www.arenapharm.com, with a replay available for 30 days after the event. Arena focuses on delivering essential medicines to patients, emphasizing urgency and innovative approaches in a dynamic market.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced on November 15, 2020, that its Compensation Committee has granted stock options and restricted stock units (RSUs) to 13 new employees. A total of 96,025 stock options and 17,590 RSUs were awarded as incentives for joining the company. The stock options have an exercise price of $66.68 and a seven-year term, vesting over four years. RSUs will also vest over four years. These grants comply with Nasdaq Listing Rule 5635(c)(4), which allows inducement grants to new employees.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced its Q3 2020 financial results, reporting revenues of $20,000, down from $1.4 million in Q3 2019. The net loss increased to $97.4 million, with a diluted loss per share of $1.69. R&D expenses rose to $79.8 million due to advancing clinical studies. Notably, the ADVISE trial results support a Phase 3 program for etrasimod. Arena also completed enrollment for the CAPTIVATE Phase 2b trial and initiated several new trials in their pipeline. Cash, cash equivalents, and marketable securities stood at $1.2 billion at the end of Q3.

Arena Pharmaceuticals, Inc. reported favorable topline results from its Phase 2b ADVISE clinical trial of etrasimod for moderate-to-severe atopic dermatitis (AD). The trial met key objectives, showcasing significant safety and early efficacy, with one-third of participants achieving clear skin at week 12. However, etrasimod did not meet its primary endpoint for EASI change. A post-hoc analysis revealed that the drug shows a statistically significant effect when accounting for dose interruptions. Arena plans to advance etrasimod to a Phase 3 program based on these findings.